|
|
|
|
|
|
|
The diabetic drug Avandia (Rosiglitazone) has been on the market since 1999. Since the drug has come onto the market, Avandia has had many safety concerns. Most recently, it has been found that those taking Avandia, especially women, are at a greater risk for bone fractures.
What is Avandia?
Avandia (Rosiglitazone) is a member of the thiazolidinedione class and is used in patients with Type 2 diabetes. This drug works by lowering blood sugar in diabetic patients by improving insulin sensitivity in the body. Rosiglitazone binds to a receptor that is most commonly found in fat tissue, muscle, and liver. By binding to this receptor, rosiglitazone activates glucose transport and utilization.
What have the studies found?
One study looked at 12 years of data on diabetic patients. The researchers compared 1,020 patients who suffered a fracture to 3,728 patients who did not break any bones. The study found that those who were taking Avandia for 1 year or more had double the fracture risk then other patients. Another study found that women taking Avandia were more at risk for upper arm, hand, and foot fractures.
|
|
|
|
|
|
|
|
|
|
|
What does this mean for diabetic patients?
It has been suggested that Avandia not be taken off the market because like all drugs, there are risks. However, it has been suggested that patients try other oral antidiabetic drugs before taking Avandia. If you are currently taking Avandia, do not quit taking the medication, but talk with your physician about your options.
For more information talk to your pharmacist or physician. For more information about Avandia, please visit www.drugs.com and search Avandia.
|
|
|
|
|
|
